Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

R F Schlenk; F Stegelmann; A Reiter; E Jost; N Gattermann; H Hebart; C Waller; A Hochhaus; U Platzbecker; P Schafhausen; I W Blau; W Verbeek; F H Heidel; M Werner; H Kreipe; V Teleanu; A Benner; H Döhner; M Grießhammer; K Döhner

doi:10.1038/leu.2016.299

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

Standard

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. / Schlenk, R F; Stegelmann, F; Reiter, A; Jost, E; Gattermann, N; Hebart, H; Waller, C; Hochhaus, A; Platzbecker, U; Schafhausen, P; Blau, I W; Verbeek, W; Heidel, F H; Werner, M; Kreipe, H; Teleanu, V; Benner, A; Döhner, H; Grießhammer, M; Döhner, K.

in: LEUKEMIA, Jahrgang 31, Nr. 4, 04.2017, S. 889-895.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schlenk, RF, Stegelmann, F, Reiter, A, Jost, E, Gattermann, N, Hebart, H, Waller, C, Hochhaus, A, Platzbecker, U, Schafhausen, P, Blau, IW, Verbeek, W, Heidel, FH, Werner, M, Kreipe, H, Teleanu, V, Benner, A, Döhner, H, Grießhammer, M & Döhner, K 2017, 'Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis', LEUKEMIA, Jg. 31, Nr. 4, S. 889-895. https://doi.org/10.1038/leu.2016.299

APA

Schlenk, R. F., Stegelmann, F., Reiter, A., Jost, E., Gattermann, N., Hebart, H., Waller, C., Hochhaus, A., Platzbecker, U., Schafhausen, P., Blau, I. W., Verbeek, W., Heidel, F. H., Werner, M., Kreipe, H., Teleanu, V., Benner, A., Döhner, H., Grießhammer, M., & Döhner, K. (2017). Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. LEUKEMIA, 31(4), 889-895. https://doi.org/10.1038/leu.2016.299

Vancouver

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H et al. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. LEUKEMIA. 2017 Apr;31(4):889-895. https://doi.org/10.1038/leu.2016.299

Bibtex

@article{96c1b0b05ce5478baf02a46f0ba901f2,

title = "Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis",

abstract = "Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or thrombocytopenia and/or neutropenia. Subjects received pomalidomide 2.0 mg/day in cohort 1 (n=38) or 0.5 mg/day in cohort 2 (n=58). Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months. Response rates were 39% (95% confidence interval (CI), 26-55%) in cohort 1 and 24% (95% CI, 15-37%) in cohort 2. In a multivariable logistic regression model pomalidomide at 2.0 mg/day (odds ratio (OR), 2.62; 95% CI, 1.00-6.87; P=0.05) and mutated TET2 (OR, 5.07; 95% CI, 1.16-22.17; P=0.03) were significantly associated with responses. Median duration of responses was 13.0 months (range 0.9-52.7). There was no significant difference in response rates or duration in subjects receiving or not receiving prednisolone. Clinical trial MPNSG 01-09 is registered at ClinicalTrials.gov (NCT00949364) and clinicaltrialsregister.eu (EudraCT Number: 2009-010738-23)Leukemia advance online publication, 29 November 2016; doi:10.1038/leu.2016.299.",

author = "Schlenk, {R F} and F Stegelmann and A Reiter and E Jost and N Gattermann and H Hebart and C Waller and A Hochhaus and U Platzbecker and P Schafhausen and Blau, {I W} and W Verbeek and Heidel, {F H} and M Werner and H Kreipe and V Teleanu and A Benner and H D{\"o}hner and M Grie{\ss}hammer and K D{\"o}hner",

year = "2017",

month = apr,

doi = "10.1038/leu.2016.299",

language = "English",

volume = "31",

pages = "889--895",

journal = "LEUKEMIA",

issn = "0887-6924",

publisher = "NATURE PUBLISHING GROUP",

number = "4",

}

RIS

TY - JOUR

T1 - Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

AU - Schlenk, R F

AU - Stegelmann, F

AU - Reiter, A

AU - Jost, E

AU - Gattermann, N

AU - Hebart, H

AU - Waller, C

AU - Hochhaus, A

AU - Platzbecker, U

AU - Schafhausen, P

AU - Blau, I W

AU - Verbeek, W

AU - Heidel, F H

AU - Werner, M

AU - Kreipe, H

AU - Teleanu, V

AU - Benner, A

AU - Döhner, H

AU - Grießhammer, M

AU - Döhner, K

PY - 2017/4

Y1 - 2017/4

N2 - Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or thrombocytopenia and/or neutropenia. Subjects received pomalidomide 2.0 mg/day in cohort 1 (n=38) or 0.5 mg/day in cohort 2 (n=58). Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months. Response rates were 39% (95% confidence interval (CI), 26-55%) in cohort 1 and 24% (95% CI, 15-37%) in cohort 2. In a multivariable logistic regression model pomalidomide at 2.0 mg/day (odds ratio (OR), 2.62; 95% CI, 1.00-6.87; P=0.05) and mutated TET2 (OR, 5.07; 95% CI, 1.16-22.17; P=0.03) were significantly associated with responses. Median duration of responses was 13.0 months (range 0.9-52.7). There was no significant difference in response rates or duration in subjects receiving or not receiving prednisolone. Clinical trial MPNSG 01-09 is registered at ClinicalTrials.gov (NCT00949364) and clinicaltrialsregister.eu (EudraCT Number: 2009-010738-23)Leukemia advance online publication, 29 November 2016; doi:10.1038/leu.2016.299.

AB - Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or thrombocytopenia and/or neutropenia. Subjects received pomalidomide 2.0 mg/day in cohort 1 (n=38) or 0.5 mg/day in cohort 2 (n=58). Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months. Response rates were 39% (95% confidence interval (CI), 26-55%) in cohort 1 and 24% (95% CI, 15-37%) in cohort 2. In a multivariable logistic regression model pomalidomide at 2.0 mg/day (odds ratio (OR), 2.62; 95% CI, 1.00-6.87; P=0.05) and mutated TET2 (OR, 5.07; 95% CI, 1.16-22.17; P=0.03) were significantly associated with responses. Median duration of responses was 13.0 months (range 0.9-52.7). There was no significant difference in response rates or duration in subjects receiving or not receiving prednisolone. Clinical trial MPNSG 01-09 is registered at ClinicalTrials.gov (NCT00949364) and clinicaltrialsregister.eu (EudraCT Number: 2009-010738-23)Leukemia advance online publication, 29 November 2016; doi:10.1038/leu.2016.299.

U2 - 10.1038/leu.2016.299

DO - 10.1038/leu.2016.299

M3 - SCORING: Journal article

C2 - 27774990

VL - 31

SP - 889

EP - 895

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 4

ER -